Heidemann E, Schmidt H, Schüch K, Ostendorf P, Waller H D
Klin Wochenschr. 1986 Feb 3;64(3):125-30. doi: 10.1007/BF01732635.
Twenty-one patients with acute and chronic leukemia or severe aplastic anemia were studied for NK activity against a thymoma cell line (Thy 121) before and after allogeneic bone marrow transplantation. The means of the pretransplant and post-transplant levels did not differ from the mean of 134 NK determinations in 67 healthy donors. There was no correlation between pretransplant NK levels and the appearance of graft-versus-host disease. Three weeks following bone marrow transplantation, pretransplant NK levels were observed. The sensitivity of NK cells to interferon was the same as in normal donors both before and after bone marrow transplantation. In contrast to methotrexate, cyclosporin A inhibited NK activity in patients and controls in vitro. In vivo cyclosporin A treatment, however, did not decrease NK levels in bone marrow recipients.
对21例急性和慢性白血病或严重再生障碍性贫血患者在异基因骨髓移植前后针对一种胸腺瘤细胞系(Thy 121)的自然杀伤(NK)活性进行了研究。移植前和移植后水平的均值与67名健康供者134次NK测定的均值无差异。移植前NK水平与移植物抗宿主病的出现之间无相关性。骨髓移植后三周,观察到移植前的NK水平。骨髓移植前后,NK细胞对干扰素的敏感性与正常供者相同。与甲氨蝶呤不同,环孢素A在体外抑制患者和对照组的NK活性。然而,在体内,环孢素A治疗并未降低骨髓接受者的NK水平。